Market Place
Sourcing Support
Kyowa Kirin Announces Positive Data For Mogamulizumab At EORTC 2024
08 Oct 2024 //
BUSINESSWIRE
Kyowa Kirin, NewBridge To Improve Rare Disease Medicine Access In MENA
08 Aug 2024 //
BIOSPECTRUM ASIA
Poland Approves POTELIGEO® Reimbursement For MF And SS
31 Jul 2024 //
BUSINESSWIRE
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO
21 Sep 2023 //
BUSINESSWIRE
Innate Present Data From PII TELLOMAK Trial Demonstrating Activity of Lacutamab
10 Dec 2022 //
BUSINESSWIRE
Kyowa Kirin`s Mogamulizumab Receives Supplemental Approval in the U.S.
30 Mar 2022 //
FDA
NICE recommends mogamulizumab for treatment of ultra-rare blood cancers
11 Nov 2021 //
PHARMAFILE
Kyowa Kirin: New Real World Evidence Underlines Benefits of POTELIGEO for CTCL
14 Oct 2021 //
BUSINESSWIRE
NICE to reassess Kyowa Kirin’s Poteligeo
15 Jun 2021 //
PHARMATIMES
NICE will revisit appraisal of Kyowa Kirin`s POTELIGEO
11 Jun 2021 //
BUSINESSWIRE
NICE will revisit appraisal of Kyowa Kirin`s POTELIGEO
11 Jun 2021 //
BUSINESSWIRE
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response
10 Jun 2021 //
BUSINESSWIRE
NICE rejects NHS funding for Kyowa Kirin`s Poteligeo
30 Jul 2020 //
PHARMA TIMES
Kyowa Kirin makes POTELIGEO® (mogamulizumab) available in Europe
16 Jun 2020 //
PHARMAWEB
Kyowa Kirin launches Poteligeo in Germany to treat patients with rare cancers
15 Jun 2020 //
PHARMABIZ
Kyowa Kirin Holdings BV`s Poteligeo (mogamulizumab) Receives Approval in US
28 Jan 2019 //
EMA
CHMP puts 13 therapies forward for EU approval
24 Sep 2018 //
PHARMA TIMES
Kyowa Kirin announces that mogamulizumab has CHMP +ve opinion
22 Sep 2018 //
PR NEWSWIRE
CHMP Backs 13 New Medicines, Maintains Negative Opinion of Sarepta’s Exondys
21 Sep 2018 //
RAPS
FDA Approves Eight Novel Drugs in August
03 Sep 2018 //
BIOSPACE
Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab
10 Aug 2018 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.